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Abstract: The neurodegenerative disorder Alzheimer’s disease (AD) is the cause of approximately 60% of
the world’s 35 million patients suffering from dementia. Current research focuses here are on association
with other diseases such as diabetes type 2 (T2DM), possible genetic markers, specific signal transduction
pathways within the brain and potential protein modification, because the pathogenesis and etiology of
AD are still not fully understood. Specifically association of T2DM with AD came to the focus with the
so-called ”Rotterdam study” in 1999, indicating that T2DM doubles the risk of developing AD. In the
meantime, it is known that the prevalence rate in patients with T2DM is 30%. Drugs commonly used
in the treatment of T2DM such as peroxisome proliferator-activated receptors gamma (PPAR￿) agonists
show improvement of the cognitive abilities in patients with early stage of dementia, with potential ther-
apeutically relevance. Therefore it is important not only to investigate a link between these diseases,
but also to investigate the insulin signaling pathway in the brain of AD patients. In order to investigate
this complex issue in more details and demonstrate additional links between T2DM and AD, the present
study used several basic biological methods to clarify the question: ”Is impaired insulin signaling pathway
within the brain crucial for the development of AD?” from several points of view. The methods used
in this work have been i) an analysis of single nucleotide (SNP) polymorphism of the insulin-degrading
enzyme gene (IDE) in relation to risk of AD and / or of T2DM, ii) post-mortem histochemical studies of
brain tissue of patients with only AD, with AD combined with T2DM and with only T2DM compared
with an age-matched control group, and iii.) investigations of neurochemical pathways and gene/protein
expression changes of a human cell culture as a consequences of amyloid ￿ (A￿) treatment. After analysis
of the IDE SNP polymorphism in the selected VITA (Vienna Trans Danube Aging) cohort disease-specific
effects were discovered. The upstream polymorphism (IDE2) was found to influence AD risk in a pro-
tective manner, while the downstream polymorphism (IDE7) modified the T2DM risk. Based on the
SNP results, the presented study delineate the model that IDE promoter and 3￿ untranslated region/-
downstream variation can have different effects on IDE expression, maybe a relevant endophenotype with
disorder-specific effects on AD and T2DM susceptibility. Furthermore, the human post-mortem studies
could show that both AD as well as T2DM patients had a significantly lower density of the insulin recep-
tor (IR) in the hippocampus, whereas a significantly increased density of inactive phosphorylated PPAR￿
has been found and this persisted even in patients with both diseases. Summarizing the histological
study, it was possible to reveal common histological features of AD and T2DM, but no direct connection
between the two diseases. Although AD is nowadays not only characterized by amyloid-containing plaque
deposits and by the hyperphosphorylation of tau protein, the excessive A￿42 presence in the brains of
AD patients is still playing a key role. Up to date it is still not entirely clear which physical form of
A￿42 is responsible for the development of AD. The present work investigated, what impact has the state
of aggregation of A￿42 on genes and proteins of the insulin signaling pathway and the amyloid cascade.
It could be shown that the oligomeric variant enhanced specifically the gene and protein expression of
glycogen synthase kinase (GSK) 3￿ and also the enzyme activity was significantly increased, but has in
turn strongly inhibited the IR gene and protein expression. Additionally, the effect of A￿42 on monoamine
oxidase B (MAO-B) was examined. An effect of both aggregated forms of A￿42 had on enzyme activity
was discovered. However, the fibrillar variants led to significantly increased activity of MAO-B while
the oligomeric variants inhibited the enzyme activity. Several previous studies have demonstrated the
involvement of increased MAO-B activity in AD, but the present work provides for the first time a direct
link between the states of aggregation of A￿42 to enzyme activity. Finally the results of the presented
thesis can be summarized to following conclusion: Although AD and T2DM sharing some degrees of
common features, still there is a lack of direct association, and therefore the diseases must be considered
more independent rather than linked. But the impaired cerebral insulin signaling pathway seems to be
another manifested hallmark of AD.
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Die neurodegenerative Erkrankung Alzheimer Demenz (AD) ist für etwa 60% der weltweit 35 
Millionen Demenz Patienten ursächlich. Die aktuelle Forschung konzentriert sich hierbei auf 
Assoziationen mit anderen Erkrankungen wie Diabetes Typ 2 (T2DM), potentielle genetische 
Marker, spezifische Signaltransduktionswege im Gehirn und mögliche Modifizierung von 
Proteinen, da weder die Pathogenese noch die Ätiologie von AD vollständig geklärt ist. Im 
Jahr 1999 rückte durch die so genannte "Rotterdam-Studie" eine mögliche Verbindung 
zwischen T2DM und AD in den besonderen Fokus der Wissenschaft, da die Studie darauf 
hinweist, dass T2DM das Risiko eine AD zu entwickeln verdoppeln kann. In der 
Zwischenzeit ist bekannt, dass die Prävalenz an einer AD zu erkranken bei Patienten mit 
T2DM 30% beträgt. Zusätzlich zeigten Medikamente, die häufig zur Behandlung von T2DM 
eingesetzt werden, wie PPARγ (Peroxisom-Proliferator-aktivierte Rezeptoren gamma) 
Agonisten, eine Verbesserung der kognitiven Leistung bei Patienten mit einem frühen 
Stadium der AD. Daher ist es wichtig, nicht nur eine mögliche Verbindung zwischen diesen 
Krankheiten zu untersuchen, sondern auch die Insulin-Signalwege im Gehirn von AD 
Patienten näher zu betrachten. Um dieses komplexe Thema in weiteren Details zu untersuchen 
und zusätzliche Verbindungen zwischen T2DM und AD aufzuzeigen, verwendet die 
vorliegende Studie mehrere biologische Grundlagenmethoden, um die Frage zu klären: "Ist 
ein beeinträchtigter zerebraler Insulin-Signalweg entscheidend für die Entwicklung einer 
AD?"  
Die in dieser Arbeit verwendete Methoden waren i) eine Analyse von Einzel-Nukleotid-Poly-
morphismen (SNP) des Insulin-abbauende Enzym (IDE) Gens in Bezug auf das Risiko eine 
AD und/oder T2DM zu entwickeln; ii) post-mortem histochemische Untersuchungen des 
Gehirngewebes von Patienten mit nur AD, mit AD und T2DM, und mit nur T2DM verglichen 
mit einer altersangepassten Kontrollgruppe; und iii) Untersuchungen neurobiologischer 
Signalwege und Gen-/Protein-Expressions Veränderung einer humanen Neuroblastoma Zell-
linie nach Behandlung mit Amyloid β (Aβ) Peptiden. 
Nach der Analyse der IDE-SNPs in der ausgewählten VITA (Vienna Transdanube Aging) 
Kohorte wurden krankheitsspezifische Effekte entdeckt. Der Upstream-Polymorphismus 
(IDE2) minderte das Risiko an einer AD zu erkranken, während der downstream gelegene 
Polymorphismus (IDE7) das Risiko T2DM zu bekommen, erhöhte. Basierend auf den SNP 
Ergebnissen, beschreibt die vorliegende Studie ein Modell, das Variationen innerhalb des IDE 





Expression haben können und somit potentiell Auswirkungen auf die Entwicklung von AD 
und T2DM haben können.  
Darüber hinaus konnte die menschliche post-mortem Studie zeigen, dass sowohl AD als auch 
T2DM Patienten eine signifikant geringere Dichte der Insulin-Rezeptoren (IR) im Hippo-
kampus hatten, während eine signifikant erhöhte Dichte von inaktiven phosphorylierten 
PPARγ bei allen Patientengruppen detektiert werden konnte. Die vorliegende post-mortem 
Studie konnte zwar gemeinsame histologische Merkmale von AD und T2DM aufzeigen, 
jedoch keine direkte Verbindung der beiden Erkrankungen nachweisen.  
Obwohl AD heutzutage nicht mehr nur noch durch die Amyloid-haltigen Plaqueablagerungen 
und durch die hyperphosphorylierten Tau Proteine gekennzeichnet ist, spielt das übermäßige 
Vorhandensein von Aβ42 in den Gehirnregionen von AD Patienten eine entscheidende 
Schlüsselrolle. Bis dato ist es immer noch nicht vollständig geklärt, welche physikalische 
Form von Aß42 verantwortlich für eine Entwicklung von AD ist. Die vorliegende Arbeit 
untersuchte, welche Auswirkungen die Aggregatszustände von Aß42 auf Gene und Proteine 
des Insulin-Signalweges und auf die Amyloid-Kaskade haben. Es konnte gezeigt werden, dass 
die oligomere Variante von Aß42 speziell die Gen- und Proteinexpression von Glykogen-
Synthase Kinase (GSK) 3β als auch ihre Enzymaktivität deutlich erhöht hatte, jedoch im 
Gegenzug die IR Gen- und Proteinexpression stark gehemmt hatte. Zusätzlich wurde die 
Wirkung von Aß42 auf die Monoamin Oxidase-B (MAO-B) untersucht. Es wurde ein Effekt 
beider untersuchten aggregierten Formen von Aß42 auf die Enzymaktivität entdeckt. Jedoch 
führte hier die fibrilläre Variante zu einer deutlich erhöhten Aktivität von MAO-B, während 
die oligomere Variante die Enzymaktivität inhibiert. Frühere Studien konnten bereits eine 
Beteiligung von erhöhter MAO-B-Aktivität in AD nachweisen, aber die vorliegende Arbeit 
zeigt erstmals eine direkte Verbindung zwischen den Aggregatzuständen von Aß42 auf die 
Enzymaktivität auf.  
Abschließend können die Ergebnisse der vorliegenden Arbeit zu folgenden Schluss-
folgerungen zusammengefasst werden: 
Obwohl AD und T2DM bis zu einem gewissen Grad gemeinsame Merkmale aufzeigen, fehlt 
es an einer direkten Verbindung, und somit sollten die Krankheiten weiterhin eher unabhängig 
als miteinander verbunden betrachtet werden. Jedoch scheint die Beeinträchtigung des 






The neurodegenerative disorder Alzheimer's disease (AD) is the cause of approximately 60% 
of the world's 35 million patients suffering from dementia. Current research focuses here are 
on association with other diseases such as diabetes type 2 (T2DM), possible genetic markers, 
specific signal transduction pathways within the brain and potential protein modification, 
because the pathogenesis and etiology of AD are still not fully understood. Specifically 
association of T2DM with AD came to the focus with the so-called "Rotterdam study" in 
1999, indicating that T2DM doubles the risk of developing AD. In the meantime, it is known 
that the prevalence rate in patients with T2DM is 30%. Drugs commonly used in the treatment 
of T2DM such as peroxisome proliferator-activated receptors gamma (PPARγ) agonists show 
improvement of the cognitive abilities in patients with early stage of dementia, with potential 
therapeutically relevance. Therefore it is important not only to investigate a link between 
these diseases, but also to investigate the insulin signaling pathway in the brain of AD 
patients. In order to investigate this complex issue in more details and demonstrate additional 
links between T2DM and AD, the present study used several basic biological methods to 
clarify the question: "Is impaired insulin signaling pathway within the brain crucial for the 
development of AD?" from several points of view. The methods used in this work have been 
i) an analysis of single nucleotide (SNP) polymorphism of the insulin-degrading enzyme gene 
(IDE) in relation to risk of AD and / or of T2DM, ii) post-mortem histochemical studies of 
brain tissue of patients with only AD, with AD combined with T2DM and with only T2DM 
compared with an age-matched control group, and iii.) investigations of neurochemical 
pathways and gene/protein expression changes of a human cell culture as a consequences of 
amyloid β (Aβ) treatment. 
After analysis of the IDE SNP polymorphism in the selected VITA (Vienna Trans Danube 
Aging) cohort disease-specific effects were discovered. The upstream polymorphism (IDE2) 
was found to influence AD risk in a protective manner, while the downstream polymorphism 
(IDE7) modified the T2DM risk. Based on the SNP results, the presented study delineate the 
model that IDE promoter and 3’ untranslated region/downstream variation can have different 
effects on IDE expression, maybe a relevant endophenotype with disorder-specific effects on 
AD and T2DM susceptibility.  
Furthermore, the human post-mortem studies could show that both AD as well as T2DM 
patients had a significantly lower density of the insulin receptor (IR) in the hippocampus, 





and this persisted even in patients with both diseases. Summarizing the histological study, it 
was possible to reveal common histological features of AD and T2DM, but no direct 
connection between the two diseases. 
Although AD is nowadays not only characterized by amyloid-containing plaque deposits and 
by the hyperphosphorylation of tau protein, the excessive Aβ42 presence in the brains of AD 
patients is still playing a key role. Up to date it is still not entirely clear which physical form 
of Aβ42 is responsible for the development of AD. The present work investigated, what impact 
has the state of aggregation of Aβ42 on genes and proteins of the insulin signaling pathway 
and the amyloid cascade. It could be shown that the oligomeric variant enhanced specifically 
the gene and protein expression of glycogen synthase kinase (GSK) 3β and also the enzyme 
activity was significantly increased, but has in turn strongly inhibited the IR gene and protein 
expression. Additionally, the effect of Aβ42 on monoamine oxidase B (MAO-B) was 
examined. An effect of both aggregated forms of Aβ42 had on enzyme activity was discovered. 
However, the fibrillar variants led to significantly increased activity of MAO-B while the 
oligomeric variants inhibited the enzyme activity. Several previous studies have demonstrated 
the involvement of increased MAO-B activity in AD, but the present work provides for the 
first time a direct link between the states of aggregation of Aβ42 to enzyme activity.  
Finally the results of the presented thesis can be summarized to following conclusion:  
Although AD and T2DM sharing some degrees of common features, still there is a lack of 
direct association, and therefore the diseases must be considered more independent rather than 
linked. But the impaired cerebral insulin signaling pathway seems to be another manifested 
hallmark of AD. 
